Navigation Links
Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
Date:4/22/2008

ovember 2001, FDA approved the first biologic treatment for severe sepsis. This drug, Xigris(R), is a genetically engineered form of a naturally occurring human protein, activated Protein C. Despite the availability of Xigris(R), treatment for severe sepsis remains an area of significant unmet medical need.

About Talactoferrin Alfa

Talactoferrin, a novel dendritic cell recruiter and activator (DCRA), is a unique recombinant form of human lactoferrin, an important immunomodulatory protein. Talactoferrin is an orally administered protein that mediates its activity through the gut and the GALT - the largest lymphoid organ in the body.

In 1988, scientists at Baylor College of Medicine, Houston, Texas, discovered a way to produce this protein in the laboratory, thus paving the way for testing its potential to help fight serious diseases that cause enormous suffering worldwide.

Lactoferrin, found in the highest concentration in milk, is expressed throughout the body in immune cells and on all body surfaces exposed to the external environment. Lactoferrin plays an important role in helping to establish the immune system, including the GALT, in infants. Talactoferrin is produced in Aspergillus niger, a filamentous fungus, and is structurally identical to native human lactoferrin in all material respects, differing only in its glycosylation.

About Agennix

Agennix is a private biotechnology company developing a first-in-class molecule with activity in several types of cancer and in other indications with unmet medical needs. This molecule, talactoferrin, is a targeted dendritic cell recruiter and activator with a novel mechanism of action. Agennix is preparing to initiate Phase 3 trials in two non-small cell lung cancer indications (talactoferrin in combination with chemotherapy in previously untreated patients and talactoferrin monotherapy in patients who have failed two or more previous therapies), a Phase 2b trial in renal cell can
'/>"/>

SOURCE Agennix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
3. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
6. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
10. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
11. Metabolex Initiates Phase 1 Trial of MBX-2982
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today announced ... shares of its common stock at a price to ... to Tandem from this offering are expected to be ... other estimated offering expenses payable by Tandem. All of ...
(Date:2/26/2015)... BEND, Ind. , Feb. 26, 2015  Mobility ... announce an agreement with Bank of America (NYSE: ... consumers nationwide to receive financing of the revolutionary MV-1 ... vehicle, designed from the ground up to provide safe ... Approved applicants can use their loan to purchase a ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... Reportlinker.com announces that a new market research report ... Sanofi-Aventis: PharmaVitae Profile http://www.reportlinker.com/p0201760/Sanofi-Aventis-PharmaVitae-Profile.html ... examines the historical and forecast performance for Sanofi-Aventis ... company strategy, portfolio and pipeline analysis and assessment ...
... As technologies for fat removal become more advanced, physicians ... the body but also recycling the fat to further ... recent statistics from the American Society for Aesthetic Plastic ... two most popular invasive and non-invasive cosmetic procedures in ...
Cached Medicine Technology:Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 2Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 3Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 4Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 5Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 6Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 7The New Face of Body Contouring 2
(Date:2/28/2015)... (PRWEB) February 28, 2015 In recent years ... number of practicing physicians as a way for them to ... education regarding Cannabis as medicine. Since the FDA still lists ... few resources available to licensed physicians that can help ... patient. Dr. Deborah Malka in Santa Cruz, CA is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 With their ... Fitness has added an additional exercise to their already ... oblique exercise is most commonly known as, is often ... “Rope Pulls” are executed in a relatively safe manner ... and strength levels. The full description of “Rope Pulls” ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... 28, 2015 For those people who ... the Mesothelioma Applied Research Foundation (Meso Foundation) ... March 3, starting at 9:30 AM. , The live ... The broadcast can be accessed through any browser on ... , The Symposium is a unique event that covers ...
(Date:2/28/2015)... Pismo Beach, CA (PRWEB) February 28, 2015 ... the needs of Central Coast area residents, recently announced ... Whitening System. It’s a treatment option for new ... patients kick off 2015 with a bright, white smile, ... the discounted price of $299, marked down from the ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... Cardiva Medical, Inc. announced today that it has received ... for its latest technology, the Cardiva Catalyst III, which ... in the market. Built upon its predecessor, the ... which neutralizes heparin in the tissue adjacent to the ...
... 19 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... aesthetics, dermatology, environmental and nutraceutical products, today announced that ... Tuesday, June 2, 2009 at 4:30 PM Eastern Time. ... (U.S.) and 1-201-689-8471 (international). The call will also ...
... (www.meettheburns.com) targets first time athlete,s foot sufferers and ... Schering-Plough Corporation (NYSE: SGP ) ... antifungal spray for the treatment of athlete,s foot. ... spray and deodorant powder spray.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 ...
... profile "New Strategies for Optimizing CHO Performance" inside the BIO Process ... ... Fort Collins, CO (PRWEB) May 19, 2009 -- Amidst ... International Convention will be InVitria, a cell culture media supplement company ...
... patient with help from GI specialists, GI Monitor, an ... (IBD) Crohn,s and Ulcerative Colitis to track their symptoms ... N.J., May 19 WellApps, Inc. launched an iPhone ... Colitis provide accurate symptom data to their doctors for ...
... May 19 Regulatory processes differ across continents, ... pressing need to integrate the regulatory environment of ... regulations impact drug launches as less price controlled ... in regulated markets. The pharmaceutical industry, along with ...
Cached Medicine News:Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 2Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 3Health News:Nuvilex, Inc. Announces Monthly Investor Conference Call 2Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:InVitria to Present at BIO 2009 International Convention in Atlanta 2Health News:IBD Patient Launches iPhone Application to Help Doctors Treat Crohn's and Ulcerative Colitis 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4
... PC captures, displays, replays and analyzes ... proven to be effective in evaluating ... obstructive pulmonary disease.,It provides objective evidence ... , , Waveform and time-expanded ...
... Acoustic Cardioscan Viewer Phonocardiogram (PCG). The ... allows you to record, condition, display and ... stethoscope. The product acquires and displays ... to four sites, and allows user-selectable filtering ...
... The MULTIVIEW WORKSTATION enhances patient ... access, rapid assessment, decision support, and ... hospital. Part of the INFINITY Patient ... comprehensive patient information, including continuous, real-time ...
... The biograph 16 offers the ... disease diagnosis and treatment in ... delivers high-quality PET/CT whole body ... minutes. Our comprehensive suite of ...
Medicine Products: